Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alterity Therapeutics Ltd ADR (ATHE)

Alterity Therapeutics Ltd ADR (ATHE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,173
  • Shares Outstanding, K 8,867
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,870 K
  • EBIT $ 0 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.21 +2.49%
on 12/08/25
3.89 -15.42%
on 11/14/25
-0.50 (-13.19%)
since 11/12/25
3-Month
3.21 +2.49%
on 12/08/25
5.17 -36.36%
on 10/16/25
-1.59 (-32.58%)
since 09/12/25
52-Week
2.04 +61.27%
on 12/18/24
7.00 -53.00%
on 07/25/25
+1.07 (+48.20%)
since 12/12/24

Most Recent Stories

More News
Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

ATHE : 3.29 (-3.80%)
Alterity Therapeutics Reports Positive ATH434 Phase 2 Trial Results at 2025 MDS Congress

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alterity...

ATHE : 3.29 (-3.80%)
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.

ATHE : 3.29 (-3.80%)
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

ATHE : 3.29 (-3.80%)
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 3.29 (-3.80%)
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)

/PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease...

ATHE : 3.29 (-3.80%)
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 3.29 (-3.80%)
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 3.29 (-3.80%)
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 3.29 (-3.80%)
Appendix 4C - Q1 FY23 Quarterly Cash Flow Report

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

ATHE : 3.29 (-3.80%)

Business Summary

Alterity Therapeutics Limited is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset consists ATH434, to treat various Parkinsonian disorders. Alterity Therapeutics Limited, formerly known as PRANA...

See More

Key Turning Points

3rd Resistance Point 3.49
2nd Resistance Point 3.44
1st Resistance Point 3.37
Last Price 3.29
1st Support Level 3.24
2nd Support Level 3.19
3rd Support Level 3.12

See More

52-Week High 7.00
Fibonacci 61.8% 5.11
Fibonacci 50% 4.52
Fibonacci 38.2% 3.93
Last Price 3.29
52-Week Low 2.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar